Effect of Complete Revascularization in STEMI: Ischemia-Driven Rehospitalization and Cardiovascular Mortality
Miha Sustersic1, Matjaz Bunc1,2
1Department of Cardiology, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia.
Insights
Complete revascularization (CR) in ST-elevation myocardial infarction (STEMI) patients with multivessel coronary artery disease (MVD) showed a lower combined endpoint of ischemia-driven rehospitalizations and cardiovascular mortality. However, after adjustments, revascularization method did not independently predict outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Outcomes Research
Background:
- Patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) benefit from complete revascularization (CR) over incomplete revascularization (IR).
- Previous trials showed no survival benefit for CR, but positive effects on combined endpoints like repeat revascularization or rehospitalization.
- The study addresses the significant healthcare burden of STEMI rehospitalizations by examining long-term CR effects.
Purpose of the Study:
- To investigate the long-term impact of complete revascularization (CR) versus incomplete revascularization (IR) on ischemia-driven rehospitalization and cardiovascular (CV) mortality.
- To analyze the relationship between revascularization strategy and patient outcomes in STEMI with MVD.
Main Methods:
- Retrospective analysis of 235 STEMI patients with MVD who underwent primary percutaneous coronary intervention (PCI).
- Patients were categorized into CR (N=70) or IR (N=165) groups.
- The primary endpoint was a composite of ischemia-driven rehospitalization and CV mortality, with a minimum six-year follow-up.
Main Results:
- The CR group had a significantly lower combined endpoint rate (32.9%) compared to the IR group (47.3%) (log-rank p=0.025), primarily driven by lower CV mortality (12.9% vs. 23.6%, log-rank p=0.047).
- No significant difference in ischemia-driven rehospitalization rates was observed between groups (log-rank p=0.206).
- After adjusting for confounders, revascularization method did not significantly impact CV mortality (p=0.622). Predictors of the combined endpoint included age, diabetes, CKD, cardiogenic shock, CTO, and ischemia-driven rehospitalization.
Conclusions:
- While CR was associated with a lower initial combined endpoint of ischemia-driven rehospitalizations and CV mortality in STEMI patients with MVD, this benefit was not independent of other risk factors.
- Concomitant conditions like cardiogenic shock, advanced kidney disease, and older age were significant predictors of adverse outcomes, irrespective of the revascularization strategy.
- The findings emphasize the importance of comprehensive risk factor management in STEMI patients with MVD.
Abstract:
Background: Patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) who undergo complete revascularization (CR) have a more favorable prognosis than those who receive incomplete revascularization (IR), as evidenced by recent randomized controlled trials. Despite the absence of a survival benefit associated with CR in these trials, positive outcomes were ascribed to combined endpoints, such as repeat revascularization, myocardial infarction, or ischemia-driven rehospitalization. In light of the significant burden that rehospitalization from STEMI imposes on healthcare systems, we examined the long-term effects of CR on ischemia-driven rehospitalization and cardiovascular (CV) mortality in STEMI patients with MVD. Methods: In our retrospective study, we included patients with STEMI and MVD who underwent successful primary percutaneous coronary intervention (PCI) at the University Medical Centre Ljubljana between 1 January 2009, and 11 April 2011. The combined endpoint was ischemia-driven rehospitalization and CV mortality, with a minimum follow-up period of six years. Results: We included 235 participants who underwent CR (N = 70) or IR (N = 165) at index hospitalization, with a median follow-up time of 7 years (interquartile range 6.0-8.2). The primary endpoint was significantly higher in the IR group than in the CR group (47.3% vs. 32.9%, log-rank p = 0.025), driven by CV mortality (23.6% vs. 12.9%, log-rank p = 0.047), as there was no difference in ischemia-driven rehospitalization rate (log-rank p = 0.206). Ischemia-driven rehospitalization did not influence CV mortality in the CR group (p = 0.49), while it significantly impacted CV mortality in the IR group (p = 0.03). After adjusting for confounders, there were no differences in CV mortality between CR and IR groups (p = 0.622). Predictors of the combined endpoint included age (p = 0.014), diabetes (p = 0.006), chronic kidney disease (CKD) (p = 0.001), cardiogenic shock at presentation (p = 0.003), chronic total occlusion (CTO) (p = 0.046), and ischemia-driven rehospitalization (p = 0.0001). Significant risk factors for the combined endpoint were cardiogenic shock at presentation (p < 0.001), stage 4 kidney failure (p = 0.001), age over 70 years (p = 0.004), female gender (p = 0.008), and residual SYNTAX I score > 5.5 (p = 0.017). Conclusions: Patients with STEMI and MVD who underwent CR had a lower combined endpoint of ischemia-driven rehospitalizations and CV mortality than IR patients, but after adjustments for confounders, the true determinants of the combined endpoint and risk factors for the combined endpoint were independent of the revascularization method.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations


